Indeed, Burton et al. [27] provided evidence that the treatment of PCa tumor-bearing mice with a VEGFR-3 antagonist can successfully inhibit lymphangiogenesis and cancer metastasis. This evidence concerns the gene FLT4 and neoplasm.